jRCT1030260016
Recruiting
Not Applicable
An observational study to verify the safety and effectiveness of treatment using organic iodine + MD(alpha) for patients with advanced cancer (stage 3 or later) using standard and advanced test indicators
Not provided0 sites10 target enrollmentStarted: TBD
ConditionsCancer
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 10
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •A case in which organic iodine + MD(alpha) was used in a patient who was not responding to standard drugs
Exclusion Criteria
- •Patients who were unable to continue due to hypersensitivity or allergic reactions to organic iodine + MD(alpha)
- •Patients who are taking other drugs concomitantly, or patients who have previously participated in clinical trials and have not yet been on the last dose of the test drug for more than one month
- •Patients who are otherwise deemed inappropriate by the principal investigator or co-investigator
Investigators
Similar Trials
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Recruiting
Phase 1
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid TumorsAdvanced Malignant Solid Tumors2025-523931-21-00Genmab A/S77
Recruiting
Not Applicable
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)Germ Cell Tumour, Endometrial Cancer and Ovarian CancerjRCT2031260005187
Recruiting
Not Applicable
An observational study on the safety and therapeutic effects of oral administration of Quercefit in subjects with aging symptomsAge-related decline in physical function and aging-associated symptomsjRCT103026001810
Recruiting
Phase 1
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.2023-507059-32-00VarmX B.V., VarmX B.V.48